poisar

Stocks · News reference

Biohaven shares are trading higher after the company announced that the U.S. District Court for the District of Delaware ruled in its favor in the case against Avilar Therapeutics. Biohaven announced a collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to the company's Kv7 ion channel platform.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BHVN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Eric Volkman

    Why Biohaven Stock Was Rocking the Market This Week

    Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.

    BHVN
  3. SEC EDGAR

    8-K filing — Biohaven Ltd. (BHVN)

    Filed: 2026-08-26 AccNo: 0001935979-26-000072 Size: 890 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    BHVN